Democrats such as Elizabeth Warren had their eye on business and the working class during the first 2020 presidential primary debate in Miami.2020 Electionsread more
Chinese President Xi Jinping is expected to present U.S. President Donald Trump with the terms it expects the U.S. to meet before Beijing is willing to settle the countries'...World Economyread more
Huawei's legal chief told CNBC that the company makes "solutions for civil use."Technologyread more
The Chinese Ministry of Commerce maintained a firm stance against the U.S. during a weekly press conference on Thursday, less than two days ahead of a scheduled meeting...China Economyread more
Carl Icahn ratcheted up his fight with Occidental Petroleum over its pending purchase of rival Anadarko Petroleum by calling for a special shareholder meeting where he hopes...Energyread more
The issue over health insurance marked the first stark divide among the candidates, and sparked a heated back-and-forth between many of the candidates on stage.Politicsread more
The stock market is shrinking for several key reasons, but there's a way for investors to maneuver it, says Citi Research strategist Robert Buckland.Trading Nationread more
Four candidates mentioned China — but none of the Democratic contenders brought up trade in the debate.Politicsread more
Credit Suisse initiated coverage of Tesla Wednesday with an "underperform" rating and a price target 15% below where the stock closed.Marketsread more
Something unusual is happening in financial markets, and it could mean more gains lie ahead for stocks, if history is any indication.Marketsread more
Waymo has officially expanded its reach and is now making some of its self-driving minivans available for customers of ride-share firm Lyft.Transportationread more
March 16 (Reuters) - Non-invasive heart valve replacement systems from Medtronic Plc and rival Edwards Lifesciences Corp proved as good or better than open heart surgery in younger, more active patients for whom the surgical option was deemed low risk, according to trial results presented on Saturday.
Both companies already have approvals for their TAVR (transcatheter aortic valve replacement) systems for use in patients too frail to endure surgery and those deemed at intermediate risk. Approvals in low-risk patients would open up a large new population for the devices seen as vital growth drivers for the companies.
An estimated 165,000 low-risk patients suffer from severe aortic stenosis each year in the United States, Western Europe and Japan, a condition that can lead to heart failure in as little as two years, Medtronic said.
With TAVR, the replacement heart valve is threaded into place through an artery via catheter, sparing patients chest-cracking surgery.
"When I do these patients in the morning, (later that day) I find them sitting in a chair, eating dinner, asking when they can go home," said Dr. Michael Reardon, who led the Medtronic study. "As a heart surgeon, there is no incision I can make that's small enough to allow my surgical patients to do that well."
Edwards, which holds about 70 percent of the U.S. TAVR market, said it expects the global market to double to about $7 billion in 2024. The two companies have similar market shares outside the United States.
The Edwards Sapien 3 TAVR system proved superior to surgery on the main goal of its 1,000-patient trial, a composite of rate of stroke, death and rehospitalization one year after the procedure. The rate for TAVR was 8.5 percent versus 15.1 percent for surgery, data unveiled at the American College of Cardiology scientific meeting in New Orleans showed.
At 30 days, the Sapien also resulted in a lower rate of stroke - 0.6 percent versus 2.4 percent - which had been the primary safety concern when these systems were first introduced.
Medtronic's rival Evolut TAVR system met the main goal of its so-called non-inferiority trial in more than 1,4000 low-risk patients, proving as safe and effective as surgery, data presented at the same meeting showed.
The combined rate of all-cause death or disabling stroke after two years was 5.3 percent for Evolut versus 6.7 percent for surgery, a difference considered not statistically significant.
At the 30-day mark, Evolut was significantly better on safety. With TAVR, the composite rate of death or disabling stroke was 0.8 percent versus 2.6 percent for surgery. TAVR was also better on other safety measures after 30 days.
TAVR systems can cost about five times as much as traditional replacement heart valves, providing a significant source of revenue for the companies. But they can be more cost effective overall due to much shorter hospital stays and recovery times.
Jefferies analyst Raj Denhoy said he expects the TAVR market to grow in both size and competition, with Boston Scientific's Lotus system poised for potential U.S. approval this year.
TAVR "is pretty dramatic technology and it should be used in a lot more patients than it's being used in already," Denhoy said. (Reporting by Tamara Mathias in Bengaluru; editing by Bill Berkrot)